TY - JOUR
T1 - Trametinib response in heavily pretreated high-grade ovarian cancer
T2 - One step towards precision medicine
AU - Cappuccio, Serena
AU - Distefano, Maria Grazia
AU - Ghizzoni, Viola
AU - Fagotti, Anna
AU - Scambia, Giovanni
N1 - Funding Information:
We thank the pain therapists (Dr. M. R. and B. A. Z.) and the Dermatologist (Dr. P. S.) for their cooperation in the clinical care of the patient and for their suggestions for the present paper. We thank also all the personnel of our hospital for the great job they do every day. And lastly, but most importantly, we thank our patient (and all of them) for giving us the consent to share her story to improve the clinical practice and the cure for ovarian cancer. Study conception: SC, VG, GS. Collection and assembly of data: SC, VG. Manuscript writing: SC and all authors. Manuscript editing and Final approval: All authors.
Publisher Copyright:
© 2020 The Authors
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5
Y1 - 2020/5
N2 - Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to overcome histology boundaries and to avoid unnecessary toxicity. We describe the case of a patient affected by recurrent high-grade serous ovarian cancer responsive to MEK-inhibitors, who had undergone multiple lines of therapy. To our knowledge, this is the first reported case of recurrent high-grade ovarian cancer showing remarkable clinical, radiologic and biochemical response to trametinib. This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice.
AB - Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to overcome histology boundaries and to avoid unnecessary toxicity. We describe the case of a patient affected by recurrent high-grade serous ovarian cancer responsive to MEK-inhibitors, who had undergone multiple lines of therapy. To our knowledge, this is the first reported case of recurrent high-grade ovarian cancer showing remarkable clinical, radiologic and biochemical response to trametinib. This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice.
KW - Genetic testing
KW - Ovarian epithelial cancer
KW - Ovarian neoplasm
KW - Precision medicine
KW - Target therapy
KW - Trametinib
UR - http://www.scopus.com/inward/record.url?scp=85079887464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079887464&partnerID=8YFLogxK
U2 - 10.1016/j.gore.2020.100547
DO - 10.1016/j.gore.2020.100547
M3 - Article
AN - SCOPUS:85079887464
VL - 32
JO - Gynecologic Oncology Reports
JF - Gynecologic Oncology Reports
SN - 2211-338X
M1 - 100547
ER -